AMERICAN HOME ISA "STRONG BUY"

17 May 1992

Diversified US health care group American Home should see its profit/earnings multiple continue to rise; it is a "strong buy," according to analysts Barbara Ryan and Catherine Knickerbocker of Alex Brown & Sons, who expect the stock to trade at 16 times their preliminary 1991 earnings per share forecast of $5.65, or at 90-95.

They say that investors should come to recognize the acceleration in earnings growth and the improved quality of EPS. The quality of earnings has also improved substantially; and fuelling earnings now is sales growth from new drugs rather than a declining sharebase and tax rate, as in previous years, they observe.

The emphasis of the company's management is now on health care and improving profitability, the analysts say, noting that a total of 91% of AHP's earnings currently emanate from health care, compared with 74.5% in 1986. Commensurate with this shift, net margins have expanded to an estimated 19% this year from 15%, and the analysts say that they expect this to rise to 21% in 1993.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight